AngioDynamics Q1 FY2027 net loss narrows to $7.1M
AngioDynamics (NASDAQ: ANGO) reported Q1 FY2027 net loss of $7.1M, down from $10.9M YoY. Net sales rose 6.9% to $80.9M, with Med Tech sales up 13.2%. Adjusted EBITDA was $5.0M. The company announced Eric Honroth as new CEO, effective November 2, 2026. FDA approved IDE for RELIEF study on NanoKnife IRE for benign prostatic hyperplasia. Guidance reiterated: net sales $336M-$341M, adjusted EBITDA $13M-$16M.
How this was made
The 30-second read
Why it matters
Earnings beat loss expectations and reaffirmed guidance, supporting a modest price rally; CEO transition and FDA IDE may add longer‑term upside.
Market read
First‑quarter earnings and guidance for a mid‑cap med‑tech firm; relevant for healthcare sector traders.
What to watch
Tariff refunds boosted margin this quarter and may not recur, potentially dampening future profitability.
Background
AngioDynamics announced Q1 FY2027 results, highlighted Med Tech growth, new CEO appointment, and FDA IDE approval for a prostate study.
Ticker impact
Q1 FY2027 earnings released with narrowed net loss, adjusted EBITDA of $5M and reaffirmed FY guidance.
potential modest upside as market prices in improved loss profile and steady guidance
Loss per share narrowed to $0.17 from $0.26 YoY and adjusted EBITDA more than doubled, indicating operational improvement.
Market effects
MedTech segment shows double‑digit growth, may lift peer valuations in vascular and oncology device space.
U.S. small‑cap healthcare sector could see slight lift.
Limited to investors focused on U.S. med‑tech equities.
Counterpoint
Guidance unchanged despite narrowing loss may signal limited upside; investors could stay cautious.
Key entities
- personEric Honroth
New President and CEO effective Nov 2 2026.
- regulatorFDA
Granted IDE approval for RELIEF study of NanoKnife IRE.
